Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 16/20 | 0.68 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798340 | 1.00 | HSD17B3 (0.68) | HSD17B3NOTUMCYP11B1CYP11B2BRD4 | |
| SCHEMBL4798815 | 0.91 | HSD17B3 (0.68) | HSD17B3NOTUMBRD4BRD2BRD3 | |
| SCHEMBL4798832 | 0.91 | HSD17B3 (0.68) | HSD17B3NOTUMBRD4BRD2BRD3 | |
| SCHEMBL4799771 | 0.90 | HSD17B3 (0.70) | HSD17B3CYP11B1CYP11B2 | |
| SCHEMBL4799778 | 0.90 | HSD17B3 (0.70) | HSD17B3CYP11B1CYP11B2 | |
| SCHEMBL4800596 | 0.87 | HSD17B3 (0.73) | HSD17B3CYP11B1CYP11B2 | |
| SCHEMBL4800587 | 0.87 | HSD17B3 (0.73) | HSD17B3CYP11B1CYP11B2 | |
| SCHEMBL4796817 | 0.87 | HSD17B3 (0.54) | HSD17B3NOTUM | |
| SCHEMBL4796810 | 0.87 | HSD17B3 (0.54) | HSD17B3NOTUM | |
| SCHEMBL4795480 | 0.86 | HSD17B3 (0.65) | HSD17B3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | HSD17B3 1/4885NOTUM 465/4885CYP11B1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.